Global Orphan Drug Market

  • ID: 3981301
  • Report
  • Region: Global
  • 170 pages
  • Frost & Sullivan
1 of 3
High Pricing and Undefined Reimbursement Policies will Limit the Sales of Orphan Drugs
The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great, while the promise for recouping financial costs is not guaranteed.

This study covers the spectrum of orphan diseases and highlights drugs already marketed as well as those in the development pipeline for them. Regional highlights, market opportunities, companies to watch, and legislative timelines are provided. This snapshot captures the global orphan drug landscape as of June 2016.

Key Questions this Snapshot will Address:
  • What therapeutic areas are currently the major focus for orphan drug development?
  • What key companies should be watched in the orphan drug development area?
  • What is the global timeline for the implementation of orphan drug legislation?
  • What are some of the cost implications for orphan drug therapeutics?
  • What are the challenges to development and commercialization of orphan drugs?
  • What challenges do payers face related to the high cost of orphan drug therapeutics?
Note: Product cover images may vary from those shown
2 of 3
1. Executive Summary
  • Scope and Segmentation
  • Key Questions this Snapshot will Address
  • Key Takeaways-Orphan Drug Market
  • Executive Summary-Market Snapshot
2. Commercialization Analysis
  • 8 Big Market Themes for Orphan Drugs
  • A Vibrant Ecosystem
  • Cancer Therapies Remain the Largest Orphan Drug Segment
  • Global Overview and Analysis
  • Regional Highlights
  • Game-changing Companies
  • Companies to Watch
  • New Market Opportunities-Orphan Drugs
  • Key 2016 Predictions-Orphan Drug Market
  • Timeline of Orphan Drug Legislation
  • Disruptive Technologies and Advances in this Field
  • Overall Environmental Impact Factors
  • Orphan Drug Payer Environment
  • A Snapshot of Global Drug Price Control Methods
3. Conclusion and Take Home Points
  • Key Conclusions
  • The Last Word-3 Big Predictions
  • Legal Disclaimer
4. Appendix A-Orphan Diseases with FDA-approved Therapies
  • Orphan Diseases with FDA-approved Therapies
5. Appendix B-Pipeline Analyses for Select Rare Diseases
  • Top Indications by Activity and Disease Overview-Blood and Lymphatic System Diseases
  • SCD-Orphan Drugs on the Market
  • SCD-Orphan Drugs in Development
  • MDS-Orphan Drugs on the Market
  • MDS-Orphan Drugs in Development
  • TTP-Orphan Drugs in Development
6. Pipeline Analyses for Select Rare Diseases-Cardiovascular Diseases
  • Top Indications by Activity and Disease Overview
  • PAH-Orphan Drugs on the Market
  • PAH-Orphan Drugs in Development
  • Calciphylaxis-Orphan Drugs in Development and on the Market
7. Pipeline Analyses for Select Rare Diseases-Lung Diseases
  • Top Indications by Activity and Disease Overview
  • CF-Orphan Drugs on the Market
  • CF-Orphan Drugs in Development
  • IPF-Orphan Drugs on the Market
  • IPF-Orphan Drugs in Development
8. Pipeline Analyses for Select Rare Diseases-Congenital and Genetic Diseases
  • Top Indications by Activity and Disease Overview
  • Fragile X Syndrome-Orphan Drugs in Development
  • HIBM-Orphan Drugs in Development
9. Pipeline Analyses for Select Rare Diseases-Connective Tissue/Skin Diseases
  • Top Indications by Activity and Disease Overview
  • SSc-Orphan Drugs in Development
  • EB-Orphan Drugs in Development
10. Pipeline Analyses for Select Rare Diseases-Digestive/Nutritional Diseases
  • Top Indications by Activity and Disease Overview
  • Ped CD-Orphan Drugs on the Market
  • Ped CD-Orphan Drugs in Development
  • Ped UC-Orphan Drugs on the Market
  • Ped UC-Orphan Drugs in Development
  • Pouchitis-Orphan Drugs in Development
11. Pipeline Analyses for Select Rare Diseases-Endocrine Diseases
  • Top Indications by Activity and Disease Overview
  • T1D with Residual Beta-cell Function-Orphan Drugs in Development
12. Pipeline Analyses for Select Rare Diseases-Exposure/Toxicity
  • Top Indications by Activity and Disease Overview
  • ARS-Orphan Drugs in Development
13. Pipeline Analyses for Select Rare Diseases-Eye Diseases
  • Top Indications by Activity and Disease Overview
  • RP-Orphan Drugs in Development
  • Stargardt Disease-Orphan Drugs in Development
  • Uveitis-Orphan Drugs on the Market
  • Uveitis-Orphan Drugs in Development
14. Pipeline Analyses for Select Rare Diseases-Immunological/Inflammatory Diseases
  • Top Indications by Activity and Disease Overview
  • Behcet's Disease-Orphan Drugs in Development
15. Pipeline Analyses for Select Rare Diseases-Infectious/Parasitic Diseases
  • Top Indications by Activity and Disease Overview
  • CMV Infection-Orphan Drugs on the Market
  • CMV Infection-Orphan Drugs in Development
  • Malaria-Orphan Drugs on the Market
  • Malaria-Orphan Drugs in Development
  • Leishmaniasis-Orphan Drugs on the Market
  • Leishmaniasis-Orphan Drugs in Development
16. Pipeline Analyses for Select Rare Diseases-Metabolic Diseases
  • Top Indications by Activity and Disease Overview
  • MPS-Orphan Drugs on the Market
  • MPS-Orphan Drugs in Development
  • Acromegaly-Orphan Drugs on the Market
  • Acromegaly-Orphan Drugs in Development
  • Urea Cycle Disorders-Orphan Drugs on the Market
  • Urea Cycle Disorders-Orphan Drugs in Development
  • NPC Disease-Orphan Drugs on the Market
  • NPC Disease-Orphan Drugs in Development
  • Pompe Disease-Orphan Drugs on the Market
  • Pompe Disease-Orphan Drugs in Development
17. Pipeline Analyses for Select Rare Diseases-Musculoskeletal Diseases
  • Top Indications by Activity and Disease Overview
  • DMD-Orphan Drugs in Development
  • SMA-Orphan Drugs in Development
18. Pipeline Analyses for Select Rare Diseases-Neurologic Diseases
  • Top Indications by Activity and Disease Overview
  • ALS-Orphan Drugs in Development
  • HD-Orphan Drugs on the Market
  • HD-Orphan Drugs in Development
  • FA-Orphan Drugs in Development
19. Pipeline Analyses for Select Rare Diseases-Rare Cancers
  • Top Indications by Activity and Disease Overview
  • Pancreatic Cancer-Orphan Drugs on the Market
  • Pancreatic Cancer-Orphan Drugs in Development
  • Glioma-Orphan Drugs on the Market
  • Glioma-Orphan Drugs in Development
  • AML-Orphan Drugs on the Market
  • AML-Orphan Drugs in Development
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll